This study focuses on a new treatment called azer-cel for adults with two types of blood cancer: relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). Relapsed/refractory means the cancer has come back or hasn’t responded to previous treatments. Azer-cel is a type of therapy called CAR T-cell therapy, which uses special cells that can attack cancer cells. Before receiving azer-cel through an IV (a tube in the vein), participants will undergo lymphodepletion, a process to lower certain blood cells to make the treatment work better. Participants will be monitored for up to 15 years to ensure their safety and see how well the treatment works.

• The study requires long-term follow-up, up to 15 years.
• Participants must have tried at least two other cancer treatments before.
• The study involves regular monitoring after receiving azer-cel.